Last reviewed · How we verify
HS-10353
At a glance
| Generic name | HS-10353 |
|---|---|
| Also known as | HS-10353 capsules |
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of HS-10353 in Chinese Participants. (PHASE1)
- A Study of HS-10353 in Adult Participants With Major Depressive Disorder (PHASE2)
- A Phase II Study of HS-10353 in Participants With Postpartum Depression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10353 CI brief — competitive landscape report
- HS-10353 updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI